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Summary
NGF has been implicated in forebrain neuroprotection from
amyloidogenesis and Alzheimer’s disease (AD). However, the
underlying molecular mechanisms are still poorly understood.
Here, we investigated the role of NGF signalling in themetabolism
of amyloid precursor protein (APP) in forebrain neurons using
primary cultures of septal neurons and acute septo-hippocampal
brain slices. In this study, we show that NGF controls the basal
level of APP phosphorylation at Thr668 (T668) by downregulating
the activity of the Ser/Thr kinase JNK(p54) through the Tyr kinase
signalling adaptor SH2-containing sequence C (ShcC). We also
found that the specific NGF receptor, Tyr kinase A (TrkA), which is
known to bind to APP, fails to interact with the fraction of APP
molecules phosphorylated at T668 (APPpT668). Accordingly, the
amount of TrkA bound to APP is significantly reduced in the
hippocampus of ShcC KO mice and of patients with AD in which
elevated APPpT668 levels are detected. NGF promotes TrkA binding
to APP and APP trafficking to the Golgi, where APP–BACE
interaction is hindered, finally resulting in reduced generation
of sAPPb, CTFb and amyloid-beta (1-42). These results demonstrate
that NGF signalling directly controls basal APP phosphorylation,
subcellular localization and BACE cleavage, and pave the way for
novel approaches specifically targeting ShcC signalling and/or the
APP–TrkA interaction in AD therapy.
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Introduction
Accumulating evidence suggests that the NGF signalling system may be
disrupted early in sporadic AD. In particular, alterations of the NGF
signalling system in the basal forebrain correlate more robustly than the
amyloid load with cognitive deficits in mild cognitive impairment (MCI)
and with MCI progression towards AD (Mufson et al., 2012).
Consistent with these findings, antibody-mediated neutralization of
NGF causes increased amyloid in AD11 mice (Ruberti et al., 2000).
Moreover, in vitro models of NGF deprivation show that amyloid
accumulation is induced and AD pathology is mimicked in PC12 and
hippocampal neurons (Matrone et al., 2008a,b); this has been referred
to as ‘Alzheimer’s-like molecular syndrome’ (Calissano et al., 2010).
Furthermore, NGF treatment can ameliorate cognition and amyloido-
genesis in AD transgenic models (Yang et al., 2014), and AD clinical
trials based on NGF gene therapy have produced promising results with
respect to cognitive preservation (Rafii et al., 2014).
Despite these findings, the molecular mechanisms underlying the
neuroprotective action of NGF in AD-like neurodegeneration remain
unclear. In particular, elucidating how NGF modulates APP processing in
neurons is critical for our basic understanding of the phenomenon and
for the early diagnosis and treatment of AD.
Amyloid precursor protein (APP) can be processed via alternative
physiological or amyloidogenic pathways depending on whether cleav-
age occurs via alpha secretase 10/17 (ADAM 10/17) or beta secretase 1
(BACE1) in neurons, which causes the generation of alpha (sAPPa, CTFa)
or beta (sAPPb, CTFb) products, respectively (Bernstein et al., 2009;
Vassar et al., 2014).
APP phosphorylation pattern has been reported to be crucial for APP
binding to cytosolic interactors and for its subcellular trafficking and
final processing (Suzuki & Nakaya, 2008; Tamayev et al., 2009).
Particularly, phosphorylation of APP at T668 (APP695 isoform number-
ing) increases the beta product levels by facilitating exposure to and
cleavage by BACE in human patients with AD and transgenic models
(Lee et al., 2003; Shin et al., 2007). The APPpT668 form is neuron-
specific, highly expressed in AD dystrophic neurites and amyloid
plaques, and induces neurodegeneration (Lee et al., 2003; Chang
et al., 2006). Of interest, mice bearing a Thr to Ala substitution at 668
(T668A) prevent AD cognitive deficits when crossed to the FDDKI mouse
model of dementia (Lombino et al., 2013). Accordingly, the inhibition/
reduction of T668 phosphorylation may be a potential target for AD
therapy (Chang et al., 2006).
Despite many studies on the anti-amyloidogenic action of NGF in the
brain, to date the effect of NGF on APPT668 phosphorylation has not yet
been investigated. Thus, we investigated the NGF-mediated control of
APP phosphorylation/processing in the forebrain and the underlying
molecular mechanisms using in vitro (primary septal neurons), ex vivo
(septo-hippocampal [SH] slices), and in vivo (KO mice and AD brain
tissues) experimental paradigms.
Our results show that NGF rescues neurons from JNK(p54)-mediated
phosphorylation of APP through its early-downstream signalling adaptor
ShcC. The reduction in APP phosphorylation induced by NGF favours APP
binding to its receptor TrkA, while affecting APP interaction with BACE,
and reduces the generation of beta products, such as CTFb and amyloid
(1-42). These findings suggest that NGF control of APP phosphorylation
and the subsequent events are potentially disrupted in the human AD
brain where the APPpT668 level is elevated and the APP–TrkA interaction
is dramatically reduced.
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Overall, our data support a role of APP (T668) phosphorylation in the
NGF-driven control of amyloidogenesis in the basal forebrain and
suggest early-downstream effectors of the NGF pathway as targets in
the development of novel anti-amyloidogenic therapies for AD.
Results
NGF controls basal APP phosphorylation at T668
The phosphorylation of APP at T668 is known to facilitate APP
amyloidogenic processing and AD pathology (Lee et al., 2003; Chang
et al., 2006).
To assess the effect of NGF on APP phosphorylation at T668 in the
forebrain, SH slices from control mice were incubated with NGF
(100 ng mL1; 1 h) and analysed by Western blot (WB) using specific
antibodies against APPpT668 and total APP (Fig. 1A). The APPpT668 level
was significantly reduced in the NGF-treated SH slices compared with the
untreated slices (CTR, 44.4  17.5%, *P < 0.05, Fig. 1B). Next, we
restricted our analysis to the septal neurons (DIV10, E18), which are
TrkA-expressing neurons and the primary cellular target of NGF in the SH
system. We incubated mouse septal neurons with NGF (100 ng mL1;
1 h) and confirmed that the APPpT668level (Fig. 1C) was significantly
decreased after NGF treatment (72.3  6.1% of CTR, *P < 0.05;
Fig. 1D), indicating that the effect of NGF on APPpT668 is specifically
directed towards these neurons. The NGF-driven decrease in APPpT668
does not result from APP protein degradation because the total amount
of APP protein was unaffected by NGF in both paradigms (Fig. 1A,C).
The same experiment was performed using rat primary neurons with
comparable results (Fig. S1A,B).
We next assessed whether in turn NGF withdrawal promotes APP
phosphorylation by incubating SH slices with anti-NGF neutralizing
antibody. We analysed APPpT668 and total APP by WB (Fig. 1E) and
found almost doubled levels of APP phosphorylation following 6-h
incubation with anti-NGF antibody (195.9  5.3% CTR, **P < 0.01;
Fig. 1F).
We also used the classic NGF deprivation paradigm in the pheochro-
mocytoma cell line (PC12). PC12 cells were differentiated into neurons
by culturing in NGF (100 ng mL1) under serum-free conditions for
10 days. Then, the PC12-derived neurons were switched to both serum-
free and NGF-free media for the indicated time periods (300, 3 h) and
analysed by WB for APPpT668 and total APP (Fig. 1G). As shown in
Fig. 1H, the APPpT668 level progressively increased after 300 of NGF
withdrawal and reached a significantly higher level after 3 h of NGF
withdrawal (142.1  9.9% of CTR, *P < 0.05). The total APP level did
not change after 300 or 3 h of NGF deprivation.
Our data indicate that NGF controls basal APP phosphorylation at
T668 in septal neurons in vitro and ex vivo.
NGF treatment decreases activation of JNK (p54) kinase
Given that JNK (Standen et al., 2001; Colombo et al., 2009; Sclip et al.,
2011) and cyclin-dependent kinase 5 (CDK5) (Iijima et al., 2000; Liu
et al., 2003) are Ser/Thr kinases and regulate APP phosphorylation under
basal and pathological conditions, they were analysed as potential
mediators of the NGF effect on APPpT668. We incubated SH slices with
the CDK5 and JNK inhibitors roscovitine (R; 14 lM, 1 h) and SP600125
(SP; 2 lM, 1 h), respectively and found a dramatic reduction in the
APPpT668 level (Fig. 2A). The inhibitor concentrations and incubation
times were selected to produce the maximum inhibitory effect on the
specific kinase without affecting cell survival (data not shown). We
analysed APP phosphorylation levels also in mouse models of genetic
ablation of the three JNK isoforms (JNK1-3) and found reduced APPpT668
levels in the hippocampal extracts of JNK1, JNK2 and JNK3 KO mice
(n = 2 mice per genotype) (Fig. 2B).
We observed that NGF does not affect the level and/or activation of
CDK5. Briefly, SH slices were incubated with NGF (100 ng mL1, 1 h) or
roscovitine (R; 14 lM, 1 h), and WB was performed using antibodies
against CDK5 or p35, the CDK5 activator (Fig. 2C). NGF was not able to
Fig. 1 NGF controls basal APP phosphorylation at T668 in neurons. (A, C).
Representative Western blots (WB) of full-length APPpT668 and total APP on
extracts from NGF-treated (100 ng mL1, 1 h) and control (CTR) septo-
hippocampal slices (A) or mouse septal neurons (C) are shown. (B, D). The results
are reported as percentage of control SH slices (44.4  17.5% of CTR,
**P < 0.01) or septal neurons (72.3  6.1% of CTR, *P < 0.05). (E) Extracts from
SH slices incubated with anti-NGF neutralizing antibodies (NGF-dep; 6 h) were
immunoblotted with anti-phosphorylated and total APP. (F) Bar graphs depict
quantification of the immunoreactivity for the APPpT668 band normalized to the
total APP level (195.9  5.3% of CTR, *P < 0.05). (G) PC12 cells were cultured
with NGF (100 ng mL1) for 10 days (CTR) and then deprived of NGF for 300 or
3 h (NGF-dep 300 and NGF-dep 3 h, respectively). (H) Bar graphs depict
quantification of the immunoreactivity for the APPpT668 band normalized to the
total APP level (142.1  9.9% of CTR, *P < 0.05). Beta-actin was used as a
loading control. Triplicate data from 4 to 5 independent experiments were used for
the analysis. SH = septo-hippocampal.
NGF controls APP phosphorylation in APP metabolism and AD, V. Triaca et al.662
ª 2016 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
modulate CDK5 or p35 levels, while the p35 level was affected by
roscovitine, as expected (Fig. 2C). SH slices were then incubated with
NGF (100 ng mL1, 1 h) or SP600125 (SP; 2 lM, 1 h), and JNK
activation was analysed by WB. A decrease in the phosphorylation of
the two JNK bands of 46 (p46) and 54 (p54) kDa was observed upon SP
treatment, while NGF specifically affected the activation of only the p54
isoform (Fig. 2D).
Therefore, we repeated the analysis to quantify the phosphorylated
p54 level in the SH slices treated with NGF (100 ng mL1, 1 h) and
observed a significant reduction in the phosphorylation level of the JNK
(p54) isoform compared with the untreated slices (59.4  4.4% of CTR,
*P < 0.05; Fig. 2E,F). A similar correlation was also observed in mouse
septal primary neurons, in which we observed a significant decrease in
JNK(p54) phosphorylation upon NGF treatment (61.5  2.1% of CTR,
**P < 0.01; Fig. 2G,H). Given that the downregulation of p54 phos-
phorylation observed with NGF treatment was comparable to that
observed using SP600125 (Fig. 2D) and that both types of treatment
decreased the APPpT668 level (Fig. 2A), our results suggest that NGF acts
through pJNK(p54) to decrease APPpT668. When treating with NGF rat
primary neurons, we obtained comparable results (Fig. S1A,B).
Thus, our results correlate the effect of NGF on the APPpT668 level
with a specific reduction in JNK(p54) activation and indicate JNKs in the
control of APP phosphorylation in the cholinergic forebrain.
Deletion of the ShcC gene causes increased pJNK activation
and APPpT668
Isoform C of the SH2-containing sequence adaptor (ShcC) couples NGF/
TrkA activation with neuronal inhibition of JNK (Molton et al., 2003). We
thus hypothesized that ShcC signalling could act early downstream of
NGF to downregulate pJNK and, consequently, APPpT668. To investigate
this potential mechanism, we examined pJNK (Fig. 3A) expression in
hippocampal tissue from ShcC KO mice by WB and found an almost
50% increase in the pJNK level compared with the age-matched WT
mice (144  5% of WT, *P < 0.05; Fig. 3C). Consistent with our
hypothesis, the basal APPpT668 level determined by WB (Fig. 3B) was
found to be almost 50% increased (141  8% of WT, *P < 0.05,
Fig. 3C). Moreover, elevated amounts of the APP C-terminal fragment
(CTF), and in particular CTFb (as indicated by the anti-APP6E10 antibody;
Fig. 3D), in the presence of normal BACE levels (Fig. 3E) were observed
in the ShcC KO mice. The ablation of the gene product was verified
probing ShcC KO and WT tissues with specific antibodies against ShcC
(Fig 3F). The beta-amyloid (1-42) levels, measured by a highly sensitive
rodent-specific ELISA, increased in the hippocampus of ShcC KO
(16  0.6 pg mg1 proteins), as compared to age-matched control
mice (10  1.4 pg mg1 proteins, *P < 0.05; Fig. 3G).
Furthermore, NGF stimulation (100 ng mL1, 1 h, RT) of SH slices
from ShcC KO mice (ShcCKO+NGF) failed to reduce JNK activation
(102  1.1% of ShcC KO, P = 0.096) and APP phosphorylation
(104.5  5.7% of ShcC KO, P = 0.37), as shown in Fig. 3H-I. Also,
levels of CTFb are comparable between NGF-treated and untreated SH
slices from ShcC KO (Fig. 3H).
Our results indicate that ShcC deletion prevents NGF from its basal
regulation of pJNK and APPpT668 and suggest that releasing the NGF-
TrkA-ShcC control of APP metabolism leads to increased CTFb and
amyloid (1-42) generation in vivo.
APP does not interact nor colocalize with TrkA, upon
phosphorylation at T668
TrkA receptor has been shown to interact with APP in vitro and in vivo
(Tarr et al., 2002; Matrone et al., 2011). Because APP undergoes a
conformational change (Ramelot & Nicholson, 2001) upon T668
phosphorylation that detaches its cytoplasmic interactors (Ando et al.,
2001), we investigated whether T688 phosphorylation affects TrkA
binding to APP. We analysed the intracellular localization of Trk, total
APP and APPpT668 using confocal microscopy. Septal neurons were
treated with NGF (NGF; 100 ng mL1, 1 h) and assayed by double
immunofluorescence staining for Trk and APP (Fig. 4A and at low
magnification in Fig. S2A), or Trk and APPpT668 (Fig. 4B and at low
Fig. 2 NGF treatment causes decreased activation of the JNK (p54) kinase. (A). Representative WB against APPpT668 and total APP of extracts from septo-hippocampal slices
untreated (CTR) or treated with NGF (100 ng mL1, 1 h), or SP600125 (SP; 2 lM, 1 h), or roscovitine (R, 14 lM, 1 h). (B) Representative WB against full-length APPpT668
and total APP from hippocampal extracts of JNK1, JNK2 and JNK3 KO mice. (C) Extracts from control SH slices (CTR) or SH slices treated with NGF (NGF; 100 ng mL
1, 1 h) or
roscovitine (R; 14 lM, 1 h) were blotted against CDK5 and its regulatory subunit p35. (D) Representative WB of extracts from control SH slices (CTR) or SH slices treated with
NGF (100 ng mL1, 1 h) or SP600125 (SP; 2 lM, 1 h) using antibodies against pJNK and total JNK. Two bands of 46 and 54 kDa were detected by WB. (E, G). Representative
WB using antibodies against pJNK and total JNK of extracts from untreated (CTR) and NGF-treated (100 ng mL1, 1 h) SH slices (E) or mouse septal neurons (G). (F, H) The
levels of phosphorylated p54 in SH slices (F) or mouse septal neurons (H) were measured, and the ratio was calculated over the total p54 level, and expressed as percentage
of the control (59.4  4.4% of CTR, *P < 0.05 and 61.5  2.1% of CTR, **P < 0.01, respectively). Beta-actin was used as a loading control. Triplicate data from 4 to 5
independent experiments were used for the analysis. SH = septo-hippocampal, HP = hippocampus.
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magnification in Fig. S2B). Weak APP/Trk colocalization can be detected
at the plasma membrane and in the dendrites of septal neurons (CTR;
r = 0.38  0.03). Upon NGF stimulation (NGF, Fig. 4A;
r = 0.67  0.08), a stronger and statistically significant colocalization
signal (P < 0.05) was observed, mainly in the perinuclear area (inset of
Fig. 4A). Conversely, Trk and APPpT668 failed to colocalize in both the
untreated (CTR; r = 0.15  0.03) and NGF-stimulated (NGF;
r = 0.12  0.03) neurons (Fig. 4B) even though the APPpT668 staining
was present and diffuse in both the cell soma and dendrites. No
statistical significance in pixel colocalization of Trk and APPpT668 was
found in the NGF-treated and untreated neurons (Costes threshold,
P < 0.5; (Costes et al., 2004)).
Moreover, to investigate whether TrkA and APPpT668 interact, we
resorted to immunoprecipitation (IP) analyses. Lysates of hippocampal
tissues from C57/Bl6J mice were subjected to IP with a specific anti-TrkA
antibody, and then probed with anti-APPpT668 or total APP (22c11) and
trk antibodies. We confirmed that APP co-immunoprecipitates with
TrkA, as expected (Fig. 4C). In contrast, under the same experimental
conditions, APPpT668 failed to co-immunoprecipitate with TrkA (Fig. 4C).
The specific interaction of TrkA with APP and not APPpT668 was further
confirmed by IP studies with SH slices. The lack of an APPpT668–TrkA
association was also observed in both the untreated and NGF-treated SH
slices (Fig. 4D) even though the amount of total APP that immunopre-
cipitated with TrkA increased upon NGF treatment (Fig. 4D).
Our data indicate that NGF stimulation promotes APP binding to its
receptor TrkA but that only the fraction of APP that is not phospho-
rylated at T688 is able to interact with TrkA. Therefore, it was not
surprising to observe that TrkA IP by APP was almost completely lost in
the ShcC KO mice (Fig. 4E), a mouse model with elevated APPpT668
(Fig. 3B) Furthermore, we investigated the Tyr 490-phosphorylated form
of TrkA (pTrkA) because of the selective NGF-driven docking of Shc to
pTrkA. The levels of APP (Fig. 3B,D; Fig. 4E) and pTrkA (Fig. 4E) in the
ShcC KO mice were found to be unaffected. The weak residual APP–
TrkA binding observed in the ShcC KO mice may result from the
presence of other Shc isoforms in the adult brain, presumably ShcB (Liu &
Meakin, 2002).
We also studied APPpT668 and Trk localization in the absence of ShcC
by double IF of coronal brain sections from perfused ShcC KO (Fig. 4F)
and WT age-matched mice (not shown). In particular, the cholinergic cell
soma in the medial septum (MS) and diagonal band of Broca and their
terminals innervating the CA1 region of the hippocampus (HP) were
analysed in ShcC KO. The analysis confirmed in vitro confocal imaging
and showed that Trk and APPpT668 do not colocalize in vivo in ShcC KO
mice, neither in the MS (r = 0.03  0.01) nor in the CA1
(r = 0.08  0.01).
These data indicate that TrkA will colocalize and interact with APP as
long as none of it is phosphorylated at T668. Accordingly, the APP–TrkA
interaction is significantly affected in the ShcC KO brain, where high
levels of APP phosphorylation occur.
The APP–TrkA interaction is significantly affected in the
hippocampus of AD patients
We hypothesized that the APP–TrkA interaction is affected in the AD
brain, where an elevated APPpT668 level is often reported (Lee et al.,
2003; Chang et al., 2006). To test this hypothesis, we analysed the
Fig. 3 Deletion of the ShcC gene results in increased levels of pJNK, APPpT668, sAPPb, CTFb and amyloid-beta (1-42). (A, B) Representative WB of hippocampal extracts from
ShcC KO (n = 3) and WT (n = 3) mice using antibodies against pJNK and total JNK (A), or APPpT668 and C-terminal APP (B). (C) The graph illustrates the optical density
analysis of pJNK (144  5% of WT, *P < 0.05) and APPpT668 (141  8% of WT, *P < 0.05) measured over total JNK and APP in ShcC KO mice, and the values are reported
as a percentage of the values in WT mice. (D–F) A representative WB of hippocampal extracts from ShcC KO and age-matched WT mice probed with specific
antibodies against APP (APP C-ter and 6E10; D), BACE (E) and ShcC (F). (G) Endogenous amyloid-beta (1-42) levels in hippocampal extracts of ShcC KO (16  0.6 pg mg1
proteins) and age-matched wild-type mice (10  1.4 pg mg1 proteins, *P < 0.05). N = 3 mice per genotype were used for this analysis. (H, I) SH slices from ShcC KO mice
were incubated with NGF (100 ng mL1, 1 h), extracted and probed for phosphorylated and total APP and JNK, and the CTFb (H). The data are reported as percentage of
control in the graph in (I). Levels of pJNK (102  1.1% of ShcC KO; P = 0.096) and APPpT668 (104.5  5.7% of ShcC KO; P = 0.37) are unchanged following NGF
incubation. Beta-actin was used as a loading control. Data from two separate experiments with brain slices from four animals per genotype were used for the analysis.
HP = hippocampus; WT = wild-type; SH = septo-hippocampal.
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APPpT668 level using WB (Fig. 5A–C) and the APP–TrkA interaction using
IP (Fig. 5D,E) in brain samples from control subjects without neurological
diseases (CTR; n = 3), patients with AD (AD; n = 3) and subjects affected
by other neurological diseases (OND; n = 3). We observed a dramatic
increase in the APPpT668 level in the hippocampus of patients with
AD (Fig. 5A), as compared to both CTR (319.5  46.1% of CTR,
APP
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Fig. 4 TrkA colocalizes with and binds to
APP but not APPpT668. (A, B). Confocal
microscopy images of untreated (CTR) and
NGF-treated (100 ng mL1, 1 h) septal
neurons are shown. Double
immunofluorescence staining was
performed with (A) anti-APP C-ter (Y188;
red) and anti-Trk (green) or with (B) specific
anti-APPpT668 (red) and anti-Trk antibodies
(green). Representative images are from 50
neurons per experimental group. Scale bar:
5 lm. (C, D). IP with a specific anti-TrkA
antibody was performed on extracts from
control mouse hippocampal tissue (C) or
untreated (CTR) and NGF-treated (NGF;
100 ng mL1, 1 h) SH slices from C57/Bl6
mice (D). Immunoprecipitates (IPs) were
then probed using WB with antibodies
against APP (22c11) or APPpT668. Triplicate
data from hippocampal tissues and SH
slices of at least 4–5 control C57/Bl6 mice
per experimental group were used for the
analysis. (E). IP with the anti-APP C-terminal
antibody was conducted on hippocampal
extracts from ShcC KO mice (KO; n = 4)
and age-matched control mice (WT; n = 4).
IPs were probed with anti-pTrkA and with
anti-APP (22c11) antibodies. (F). Confocal
microscopy images of medial septum (MS)
and hippocampal CA1 (CA1) in coronal
brain sections of ShcC KO mice (n = 3
mice). Double immunofluorescence
staining was performed with specific anti-
APPpT668 (red) and anti-Trk antibodies
(green). Scale bars: 25 lm. IPs,
immunoprecipitate; Ft, flowthrough; Lys,
lysate; WT, wild-type; MS, medial septum;
DB, diagonal band of Broca; HP,
hippocampus; CC, Corpus Callosum; CA,
Cornus Ammonis.
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**P < 0.01; Fig. 5B) and OND (202.4  15.6% of OND, *P < 0.05;
Fig. 5C), as expected. Then, we immunoprecipitated the APP from the
CTR, OND and AD hippocampal tissue and probed the samples with a
specific anti-TrkA antibody. We found that the amount of TrkA bound
to APP was significantly lower in all three AD samples, as shown in
Fig. 5D. Analysis of the TrkA-positive co-immunoprecipitated band
relative to the input showed lower binding in AD (*P < 0.05;
56.4  12, %CTR), as compared to both CTR and OND (108 + 15,
%CTR), while no difference was found between CTR and OND
(P = 0.6) hippocampal samples.
Next, we repeated the IP analysis using the hippocampal and
cerebellar extracts from the same AD subject (AD2) and found that
the APP–TrkA interaction was almost completely undetectable in the
hippocampus of this AD patient but preserved in the AD cerebellum
(Fig. 5E).
Our data reveal that a lack of APP–TrkA binding correlates with an
elevated APPpT668 level and it is specific of neurodegenerating tissues in
humans with AD.
NGF promotes the APP binding with TrkA versus BACE1, by
inducing APP trafficking to the Golgi, and reduces beta
products generation
Finally, we investigated the effect of NGF on the APP interaction with
BACE and APP subcellular localization. Both of these events are known
to be modulated by APP phosphorylation at T668 (Lee et al., 2003;
Muresan & Muresan, 2005). For this investigation, we treated SH slices
with NGF (100 ng mL1, 1 h), performed an IP analysis with anti-APP
antibody, and probed the samples with specific anti-TrkA or anti-BACE1
antibodies. We observed that NGF increases APP binding to TrkA and
concomitantly decreases APP binding to BACE1 (Fig. 6A).
To study APP cleavage following NGF treatment, we performed WB
for APP, sAPPa, sAPPb, CTFb, BACE1 and ADAM17 (Fig. 6B) on
untreated and NGF-treated (100 ng mL1, 1 h) SH slices. We found
increased sAPPa (129.4  9.3% of CTR, *P < 0.05) and reduced sAPPb
(50.6  12.2% of CTR, *P < 0.05) and CTFb (52.5  7.3% of CTR,
*P < 0.05) expression upon NGF treatment (Fig. 6C). The levels of full-
length APP (86.2  6.9% of CTR, P = 0.12), BACE1 (92.2  18.7% of
CTR, P = 0.69) and ADAM17 (113.6  5.8% of CTR, P = 0.08) were
unaffected (Fig. 6C). Moreover, we measured endogenous amyloid-beta
(1-42) levels in the hippocampus of NGF-treated SH slices
(10  0.1 pg mg1 proteins) and found a significant reduction com-
pared to control (14.5  0.5 pg mg1 proteins, *P < 0.05, Fig. 6D).
To determine whether NGF reduces the interaction between APP and
BACE by modulating subcellular APP trafficking, we performed a
confocal imaging analysis on NGF-treated (100 ng mL1; 1 h) septal
neurons. Neurons were double-immunolabelled with several markers for
different intracellular compartments, such as giantin for the Golgi, Rab5
for early endosomes, and LAMP1 for late endosomes/lysosomes. Upon
NGF stimulation, we found an increase in APP localization at the plasma
membrane (Fig. 6E and inset of Fig. 6E, asterisks) and in cell soma, in
particular in the Golgi, as quantified with the Imaris 7.6 software
(130  9.7% of CTR, **P < 0.01; Fig. 6F; lower magnification in
Fig. S3B).
To address APP–BACE interaction in the Golgi, where APP accumu-
lates upon NGF treatment, we performed a triple immunostaining for
APP (red)/BACE1 (green)/giantin (purple) in septal neurons (Fig. 6G).
BACE1 immunoreactivity was found to be diffuse and widely distributed
throughout the cytoplasm of both unstimulated (CTR) and NGF-treated
(NGF) septal neurons. Moreover, APP and BACE immunofluorescent
signals were found to colocalize in the Golgi, although at a low extent
(Fig. 6G). Pearson’s correlation between APP and BACE within the Golgi
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Fig. 5 APPpT668 is elevated and conversely APP-TrkA binding is reduced in the AD human hippocampus. (A). A representative WB with specific antibodies against APPpT668
and total APP on human hippocampal extracts from control (CTR), AD and other neurological disease (OND). (B, C) The graph shows the quantification of the APPpT668 level,
reported as percentage of the level observed in the CTR (319.5  46.1% of CTR, **P < 0.01; B) or OND group (202.4  15.6% of OND, *P < 0.05; C). (D). IP with anti-
APP C-terminal antibody was conducted on hippocampal extracts from CTR, OND and AD hippocampi. IPs were probed using WB with specific anti-TrkA and anti-APP N-Ter
(22c11) antibodies. (E). IP with anti-APP C-terminal antibody was conducted on hippocampal and cerebellar extracts from the AD2 subject. IPs were probed using WB with a
specific antibody against TrkA and the anti-APP (22c11) antibody. b-actin was used as a loading control. CTR1-3 = Subjects without neurological diseases. Mean age at
death: 60  7 years. OND1 = Huntington’s Disease (HD); OND2 = spinocerebellar ataxia 17 (SCA17); OND3 = counter-lateral hemisphere of unilateral intracerebral
bleeding. AD1-3 = familial AD (Met146Leu mutation, PS1 gene), Clinical Dementia Rating (CDR) stage 5, Braak stage VI. Mean age at death: 48  8.2 years.
IPs = immunoprecipitates; HP = hippocampus; Crb = cerebellum; CTR, age-matched controls without neurological diseases; AD = Alzheimer’s disease; OND = other
neurological disease.
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has been measured by creating a 3D mask of the giantin-positive
volume, with the help of Volocity 6.0 (PerkinElmer). The 3D rendering of
APP (red)- and BACE (green)-positive voxels within the giantin (purple)-
positive volume in CTR and NGF-treated neurons has been reported in
the inset 3D (Fig. 6G). The results of this analysis indicate a moderate
correlation of APP and BACE colocalization in the Golgi of CTR neurons
Fig. 6 NGF favoured APP binding to TrkA instead of BACE1 and induced APP trafficking to the Golgi compartments. (A) IP with an anti-APP C-Ter antibody was conducted
on extracts from untreated (CTR) and NGF-treated (NGF; 100 ng mL1) SH slices. IPs were probed with antibodies against TrkA, BACE1 and APP (22c11). (B, C). A
representative WB (B) and statistical analysis (C) of extracts from untreated (CTR) or NGF-treated (NGF; 100 ng mL1, 1 h) SH slices for APP (86.2  6.9% of CTR, P = 0.12),
sAPPa (129.4  9.3% of CTR, *P < 0.05), sAPPb (50.6  12.2% of CTR, *P < 0.05), CTFb (52.5  7.3% of CTR; P > 0.05), BACE1 (92.2  18.7% of CTR, P = 0.69),
ADAM17 (113.6  5.8% of CTR, P = 0.08), and b-actin as a loading control, are shown. (D) Endogenous amyloid-beta (1-42) levels (pg mg1 proteins) in control (CTR;
14.5 + 0.5 pg mg1 proteins) and NGF-treated (NGF; 10 + 0.1 pg mg1 proteins, *P < 0.05) SH slices. (E–G). Confocal image analysis of untreated (CTR) and NGF-treated
(NGF; 100 ng mL1; 1 h) septal neurons. (E) Double immunostaining for APP/giantin in septal neurons is shown. (F) The quantitative analysis of the APP (red) staining in the
Golgi network (anti-giantin, green) upon NGF treatment by 3D quantification of the APP-positive voxels within the giantin-positive volume (Golgi, arrows) was performed by
the Imaris 7.6 software. The results are reported in the graph as a percentage of the value in untreated neurons (130  9.7% of CTR, **P < 0.01). Note the increase in
membrane localization of APP in septal neurons upon NGF stimulation (E, asterisks). (G) Triple immunostaining for APP (red)/BACE1 (green)/giantin (purple) in septal neurons
is shown. Note that APP immunoreactivity is enriched in the cell soma and accumulates in the Golgi upon NGF treatment, while BACE1 localization is more diffuse and
distributed throughout the cytoplasm of both unstimulated (CTR) and NGF-treated (NGF) septal neurons. APP colocalization with BACE was measured by creating a 3D mask
of the giantin-positive volume (inset 3D), with the help of Volocity 6.0 software, and was found to be significantly reduced upon NGF treatment (P < 0.05;
r = 0.323  0.049), as compared to CTR neurons (r = 0.579  0.084). Inset 3D shows rendering of APP (red) and BACE (green)-positive voxels within the giantin (purple)-
positive volume in CTR and NGF-treated neurons. Images are representatives of at least 50 neurons from 4 to 5 independent neuronal cultures. IPs = Immunoprecipitates.
Scale bars: 5 lm.
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(r = 0.579  0.084), while poor correlation was found upon NGF
treatment (r = 0.323  0.049; P < 0.05). Of note, BACE localization in
the Golgi was not affected by NGF treatment (P = 0.314; r = 0.363 
0.02), as compared to unstimulated neurons (r = 0.315  0.05).
APP trafficking to endosomes and lysosomes was also analysed. The
amounts of APP localized to the early (Rab5; Fig. S3A) endosomes were
comparable (P = 0.7) between the CTR (r = 0.6  0.2) and NGF-treated
septal neurons (r = 0.7  0.1). APP localization to lysosomes (LAMP1;
Fig. S3C) was present at a similar extent (P = 0.99) in CTR
(r = 0.5  0.2) and NGF (r = 0.5  0.1)-treated neurons, in our exper-
imental conditions.
Taken together, our data show that NGF treatment favours the APP
interaction with TrkA, promotes APP trafficking towards the Golgi,
reduces APP exposure to BACE cleavage, and finally results in the
reduction of sAPPb, CTFb and amyloid-beta (1-42) levels in the basal
forebrain neurons.
Discussion
Our study aimed to investigate NGF control of APP phosphorylation and
metabolism in the basal forebrain under physiological conditions, and
following NGF system perturbation described in AD. NGF is a pleiotropic
factor for cholinergic neurons of the basal forebrain, the main target of
Alzheimer’s disease (AD) pathology. Septal cholinergic neurons have
been shown to accumulate intracellular amyloid during aging and AD,
thus affecting neuronal activity and cognition in rodents, monkeys and
humans (Baker-Nigh et al., 2015; Norvin et al., 2015). The data
presented in this study indicate that NGF downregulates the phospho-
rylation of APP at the neuron-specific residue T668, promotes APP
binding with TrkA, and favours APP trafficking to the Golgi, at the
expense of BACE interaction and cleavage.
In detail, our findings indicate that ectopic NGF stimulation (Fig. 1A–
D) and NGF withdrawal (Fig. 1E–H), control basal APPpT668 levels in
neurons. Moreover, our results correlated the effect of NGF on the
APPpT668 level with a specific reduction in JNK(p54) activation. In fact,
APPpT668 is affected both by pharmacological inhibition of JNKs in SH
slices and by genetic ablation of the three JNK isoforms in JNK1, JNK2
and JNK3 KO mice, and of JNK2/3 in particular. Of interest to this study,
JNK3 activity has been found to increase by 35% in FAD models, which
induces amyloidogenesis and neuronal apoptosis, affects cognition
(Yoon et al., 2012), and controls APP localization (Muresan & Muresan,
2005).
As expected, also CDK5 inhibitors reduced the APPpT668 level in the
SH slices (Fig. 2A). However, NGF did not affect the expression levels of
CDK5 or its activator p35 (Fig. 2C). Conversely, NGF was able to
significantly reduce JNK activation in both the SH slices (Fig 2D–F) and
septal neurons (Fig 2G,H). In particular, NGF specifically affected
phosphorylation of the JNK(p54) band (Fig. 2F and H). Thus, a crucial
role for NGF modulation of JNK(p54) activation may be in APP
phosphorylation, metabolism and the related cognition in mammals.
Further analyses focused on the involvement of the SH2-containing
sequence C (ShcC) in these events. ShcC docking to TrkA is an early-
downstream event induced by NGF and causes the PI3K/AKT-mediated
inhibition of JNK (Pelicci et al., 2002). Thus, we analysed JNK activation
and the APPpT668 level in hippocampal extracts from ShcC KO mice and
found a dramatic rise of JNK phosphorylation (Fig. 3A,C) and a
concomitant increase in the APPpT668 level compared with age-matched
WT mice (Fig. 3B,C). Furthermore, we found a significant elevation in
the total CTF level, and in particular CTFb (Fig. 3D), while full-length APP
(Fig. 3B) and BACE (Fig. 3E) were unaffected (Fig. 3B,D). Endogenous
amyloid-beta (1-42) levels were also significantly augmented in ShcC null
mice, as measured by a rodent-specific ELISA (Fig. 3D). As a further
confirmation of the key role of ShcC in the anti-amyloidogenic NGF
pathway, NGF failed to modulate JNK and APP phosphorylation in SH
slices from ShcC KO mice (Fig. 3H,I), as well as to reduce CTFb levels
(Fig. 3H). Thus, ShcC is necessary for negative regulation of JNK
mediated APP phosphorylation, and the control of the consequent CTFb
and amyloid-beta generation in vivo.
Our data also indicate that TrkA colocalizes with APP in unstimulated
septal neurons (CTR; Fig. 4A) and interacts with APP in both hippocam-
pal tissues (Fig. 4C) and SH slices (Fig. 4D). These results are consistent
with previous studies demonstrating the APP–TrkA interaction in TrkA-
transfected 293T cells and hippocampal neurons in vitro and in vivo (Tarr
et al., 2002; Matrone et al., 2011). Moreover, using both confocal
imaging (Fig. 4A) and IP analysis (Fig. 4D), we found that the APP
association with TrkA increases after NGF treatment. However, TrkA
does not colocalize with APPpT668 under basal conditions or after NGF
treatment (Fig. 4B,C). Indeed, the lack of an APPpT668–TrkA interaction
was observed in both the control and NGF-treated SH slices, despite the
increase in the amount of total APP bound to TrkA after NGF stimulation
(Fig. 4D). These findings lead us to hypothesize that APP and TrkA only
form a complex when APP is not phosphorylated at the T668 site and
that, in turn, the reduction in the APPpT668 level induced by NGF
facilitates TrkA binding to APP. Consistent with our model, the
interaction between TrkA and APP is almost undetectable in basal
forebrain tissues of ShcC KO mice (Fig. 4E), in which an elevated level of
APPpT668 was found (Fig. 3B,C).
Previous studies have shown that transgenic mice lacking the APP–
TrkA interaction demonstrate forebrain damage and cognitive deficits
(Matrone et al., 2012). Based on the effect of APP phosphorylation on
APP–TrkA binding, the APP–TrkA interaction was investigated in the AD
human brain where elevated APPpT668 levels have been reported (Lee
et al., 2003; Chang et al., 2006). An increase in the APPpT668 level in
patients with AD was also observed in our analysis (Fig. 5A–C).
Consistent with our hypothesis, the APP–TrkA interaction was found
to be significantly affected (Fig. 5D), and in some cases lost (Fig. 5E), in
the AD hippocampus. Interestingly, the AD cerebellum (Fig. 5E), a
relatively unaffected tissue in AD (Andersen et al., 2012), and the HD
hippocampus (Fig. 5D) maintained the APP–TrkA interaction. These data
suggest that reduced APP–TrkA binding is a good correlate of AD
pathology and not just a general marker of degeneration.
Next, we investigated neuronal APP trafficking and BACE binding/
cleavage upon NGF stimulation in primary septal neurons. We found that
NGF treatment favoured binding of APP to its specific receptor TrkA at
the expense of BACE1 (Fig. 6A) and stimulated APP trafficking to the
Golgi (arrows, Fig. 6E,F), where APP–BACE colocalization is quite weak
in control neurons and further reduced upon NGF treatment of septal
neurons (Fig. 6G; inset 3D). These results are in line with recent papers
showing that although APP and BACE colocalization is detected in the
Golgi, the main neuronal site for APP shedding are the endosomes (Das
et al., 2013, 2016; Buggia-Prevot et al., 2014; Vassar et al., 2014).
Accordingly, NGF treatment promoted the anti-amyloidogenic pro-
cessing of APP in the basal forebrain, as demonstrated by the increase in
sAPPa and the concomitant decrease in sAPPb (Fig. 6B,C), CTFb (Fig. 6B,
C) and amyloid-beta 42 (Fig. 6D) levels in SH slices. Further, these events
occurred independently of both BACE and ADAM17 levels (Fig. 6B,C),
which were unaffected (Fig. 6C).
Intriguingly, it has been reported that APP is transported using the
activated NGF/TrkA-Shc signalling system in neurons (Heese et al.,
2004). Therefore, the idea of a NGF-driven trafficking of APP in septal
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primary neurons is consistent with previous and recent studies on
neuronal APP trafficking and deserves future investigation.
Conclusions
All together, these data suggest that NGF directly controls the pattern of
APP phosphorylation, its trafficking, interaction with and cleavage by
BACE, which ultimately reduces CTFb and amyloid generation in basal
forebrain neurons.
Interestingly, APP processing was found to be normal in APP(T668A)
mice, bearing a Thr to Ala point mutation (Sano et al., 2006), suggesting
that APPpT668 reduction is not sufficient per se to affect APP processing
and that instead an active NGF/TrkA–ShcC signalling system is required
for promoting APP–TrkA interaction and anti-amyloidogenic APP
processing. Further, the differential binding of APP to its interactors,
namely TrkA and BACE, impacting APP trafficking and processing in
basal cholinergic neurons is of potential interest for AD pathology,
where APP–TrkA interaction was found to be specifically affected.
Therefore, novel strategies aimed at stimulating ShcC signalling and/
or promoting TrkA–APP binding should be considered as promising
therapeutic tools for early neurodegeneration in AD.
Experimental procedures
Reagents and antibodies
Murine NGF was purified from submaxillary glands (Bocchini & Angeletti,
1969). NGF from Xiamen Bioway (Biotech Co., Ltd., Xiamen, Fujian,
China) was also used in the study. Roscovitine was purchased from
SIGMA (St. Louis, MO, USA; R7772), SP600125 from Calbiochem (San
Diego, CA, USA; 420119). Rabbit anti-TrkA (WB 1:1000, IF 1:100) was a
generous gift from Prof. L. Reichardt. The polyclonal anti-NGF antibody
used for NGF neutralization was kindly provided by D. Mercanti (CNR-
IBCN, Rome). The commercial antibodies used are listed in Table 1.
SH slices
Young adult C57/Bl6 male mice 3–5 months of age were used for the
preparation of SH slices. The animals were sacrificed by cervical
dislocation. The SH region was removed and cooled in ice-cold
oxygenated artificial cerebrospinal fluid (aCSF; 126 mM NaCl, 2.5 mM
KCl, 1.2 mM Na2HPO4, 24 mM NaHCO3, 2.4 mM CaCl2, 1.3 mM MgCl2
and 10 mM glucose). Next, 300-lm-thick slices were cut using a
McILWAIN tissue chopper (Ted Pella, Redding, CA, USA) and incubated
in aCSF (1 h) under appropriate oxygenation and pH conditions (95%
O2, 5% CO2). Slices were then exposed to the different treatments, snap
frozen and stored at 80 °C until use.
NGF withdrawal experiments were performed by incubation at
different time points (3, 6 h) of control SH slices with neutralizing titres
of anti-NGF antibody, as previously described (Matrone et al., 2008b).
Septal neurons primary culture
Septal neurons were prepared from embryonic day 17/18 (E17/18)
pregnant Wistar rats or embryonic day 16 (E16) pregnant C57/Bl6 mice,
as previously described (Hartikka & Hefti, 1988). They were seeded as
follows: 1.5 9 106 cells on poly-l-lysine (SIGMA)-coated plates (BD
Falcon, Durham, NC, USA; 353001) for biochemistry analyses and
5 9 104 cells on glass coverslips in 24-well plates (BD Falcon; 351147)
for immunofluorescence analyses. The dissociated cells were plated in
Neurobasal medium supplemented with 2% B27 (Invitrogen Inc.,
Carlsbad, CA, USA) for 10 days (37 °C, 5% CO2) and then used for
the experiments. At day 10, more than 95% cells showed positive
staining for ChAT and around 90% of ChAT-positive cells were also TrkA
positive (data not shown).
PC12 cell culture
PC12 cells were cultured in RPMI medium containing 10% horse serum
and 5% FBS. NGF deprivation was performed as previously described
(Matrone et al., 2008b). PC12 cells were incubated with NGF
(100 ng mL1) for 10 days until fully differentiated and then used as a
control (CTR) or kept in serum-free and NGF-free medium for 30 min or
3 h (NGF-dep 300; NGF-dep 3 h). Plates were frozen at 20 °C until use.
Rodent strains
All animals were handled in compliance with the national (D.Lgs26/
2014) and international guidelines for animal welfare (2010/63/EU). All
efforts were made to minimize the number of animals used and
suffering. C57/Bl6J mice and Wistar rats (HARLAN Laboratories Ltd.,
F€ullinsdorf, Switzerland) were housed at the IBCN-CNR (Italy) animal
facility. Brain tissues from male ShcC KO mice (Sakai et al., 2000),
maintained in a C57/Bl6J background, were collected from mice housed
at the Animal Facility of the ‘University of Siena’ (Italy). The JNK1-3 KO
mouse hippocampal tissues were provided by M.F. (Nistico et al., 2015).
Age-matched C57/Bl6J mice and/or tissues were used as controls in this
study.
Human brain samples
Brain tissue samples from human subjects were provided by the Regional
Neurogenetic Center (CRN, ASP CZ) of Lamezia Terme, Italy. All brain
Table 1 Antibodies used in the study
Antibody name Company and code Working dilution
APP (22c11) MILLIPORE(Temecula, CA, USA), MAB348 WB 1:1000, IF 1:200
APP C-ter
(Y188)
ABCAM(Cambridge, UK), AB32136 IF 1:100
BACE1 MILLIPORE(Temecula, CA, USA), MAB5308 WB 1:500
BACE1 PIERCE(Waltham, MA USA), PA1-20215 IF 1:150
ChAT MILLIPORE(Temecula, CA, USA), AB144P IF 1:100
APP C-ter SIGMA(St. Louis, MO, USA), A8717 WB 1:1000
APPpT668 SIGMA(St. Louis, MO, USA), A9103 WB 1:1000, IF 1:100
CDK5 SIGMA(St. Louis, MO,USA), C6118 WB 1:1000
p35 SIGMA(St. Louis, MO, USA), P9489 WB 1:1000
b-actin-HRP SIGMA(St. Louis, MO, USA), A3854 WB 1:1000
sAPPa IBL INTERNATIONAL(Hamburg, DE), 11088 WB 1:500
sAPPb IBL INTERNATIONAL(Hamburg, DE), 18957 WB 1:2000
APPpT668 CELL SIGNALING(Danvers, MA, USA), 3823s WB 1:1000, IF 1:100
pTrkA CELL SIGNALING(Danvers, MA, USA), 9141 WB 1:1000
SAPK/JNK CELL SIGNALING(Danvers, MA, USA), 9252s WB 1:1000
pJNKT183/Y185 CELL SIGNALING(Danvers, MA, USA), 9251s WB 1:1000
Trk SANTA CRUZ(Santa Cruz, CA, USA), sc7268 WB 1:1000, IF 1:100
Trk SANTA CRUZ(Santa Cruz, CA, USA), sc11 IF 1:100
Rab5 ABCAM(Cambridge, UK), AB18211 IF 1:100
Giantin ABCAM(Cambridge, UK), AB24586 IF 1:100
LAMP1 STRESSGEN(Collegeville, PA, USA),
ADIVAMEN001
IF 1:100
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donors or their legal tutors gave written informed consent during their
lifetime, and the protocol was approved by the local ethics committee.
The study was conducted with brain samples from 3 unrelated patients
affected by familial AD (FAD) and bearing the Met146Leu mutation of
the Presenilin1 gene. The mean age of death of the patients was
48  8.2 years, and they were at the terminal stage of dementia (stage
5, according to the Clinical Dementia Rating scale). For all patients, the
Braak staging for AD pathology (AD-related neurofibrillary pathology)
was VI. Brain tissues from three human subjects (CTR; 60  7 years of
age) without neurological diseases were used as control. Samples from
three subjects affected by other neurological diseases (OND) were also
analysed in this study. Specifically, the three OND subjects were affected
by spinocerebellar ataxia 17 (SCA17), Huntington’s disease (HD), and the
third subject died from accidental intracerebral bleeding in the left brain
hemisphere (the sample was taken from the counter-lateral right brain
hemisphere). Histopathological lesions suggestive of AD (neurofibrillary
pathology, deposition of Ab protein) were excluded. In details, tissues
were sampled from hippocampal gyrus (CA1, CA2, CA3 and dentate
gyrus, excluding parahippocampal gyrus and subiculum) and from
cerebellar hemispheres. The brain samples were collected at 4–36 h
postmortem and stored at 80 °C until use.
WB analysis
Brain slices, tissues samples and cultured neurons were digested in a
RIPA buffer with phosphatase and protease inhibitors (Pierce) and
centrifuged (10,000 rpm, 200). The supernatants were collected, and the
amount of total protein was determined (Quick Start Bradford Dye
Reagent, Biorad, Hercules, CA, USA). Each sample (40 lg) was
separated by SDS–PAGE in 4–12% Bis-Tris gels (Invitrogen), transferred
to nitrocellulose membranes (0.45 lM, GE healthcare, Little Chalfont,
UK) and incubated for 1 h at room temperature with 5% nonfat dry milk
in TBS-T (10 mM Tris, pH 7.5, 100 mM NaCl and 0.1% Tween-20). The
overnight incubation with primary antibody (4 °C) was followed by
incubation with the appropriate HRP secondary antibody (1:3000, Pierce,
1 h, RT) and the ECL method (GE Healthcare). The films were digitalized
using a professional scanner (HP) and quantified using IMAGE 1.63
software (NIH). Omission of the primary antibody was routinely
performed as control for antibody specificity (not shown).
Immunoprecipitation
A total of 1 mg of protein extract was added to Dynabeads-Protein G
and eluted with 0.1 M citrate buffer, pH 2.3, according to the
manufacturer’s instructions (Invitrogen). IP of APP was performed using
rabbit anti-APP C-terminal antibody (Sigma; 10 lg/50 lL beads). IP of
TrkA was performed using specific anti-TrkA antibody (4 lL/50 beads).
There were no specific bands detected by WB, when the same amount
of normal rabbit IgG (Santa Cruz, sc-2027) was used as isotypic control
for the IP (Fig. S1E).
Immunofluorescence and confocal imaging
Primary septal cell cultures were fixed for 20 min in PBS containing 4%
paraformaldehyde (PFA), permeabilized and quenched. Statistical anal-
ysis was performed and representative images were chosen among 50
primary neurons from multiple assays.
ShcC KO (n = 3) and age-matched control mice (n = 3) were
anesthetized with avertin (500 mg kg1, i.p.; Sigma-Aldrich) and
perfused transcardially with PBS, pH 7.4, followed by 4% PFA in PBS.
Then, the brains were collected, postfixed overnight (4% PFA, 4 °C) and
cryoprotected in 30% (w/v) sucrose in PBS 0.1 M (4 °C) until they sank to
the bottom, as previously described (M€uller et al., 2012). Coronal brain
sections (25 lm thick) were cut on a cryostat (Leica Microsystems) and
kept floating in PBS at 4 °C until use. Sections spanning from bregma
0.74 mm to 1.34 mm (medial septum) and from bregma 1.34 to
2.3 mm (hippocampus) were used for this analysis (Paxinos & Franklin,
2001).
Coronal brain sections or fixed primary neurons were incubated with
ammonium chloride (50 mM, RT) for 30 min, to quench autofluores-
cence and then blocked with 10% normal donkey serum (code:
01700121, Jackson Lab, Bar Harbor, ME, USA). The overnight incubation
(4 °C) with primary antibody was followed by incubation with the
appropriate combination of secondary antibodies. In particular, donkey
anti-mouse-546 and donkey anti-rabbit-488, or donkey anti-mouse-488
and donkey anti-rabbit-546 were used for double immunofluorescence;
donkey anti-mouse-647, donkey anti-goat-546 and donkey anti-rabbit-
488 were used for triple immunostaining (Life Technologies, 1 h, RT,
Carlsbad, CA, USA). Finally, DAPI (Life Technologies) was used for
counterstaining and Prolong Gold (Life Technologies) for mounting on
Superfrost Plus slides. Confocal microscopy was performed with the laser
scanning confocal microscope TCS SP5 (Leica Microsystems, Mannheim,
Germany) using a 40X (NA = 1.25) and a 63X (NA = 1.4) oil-immersion
lens. An UV diode laser operating at 405 nm, an Argon laser at 488 nm
and HeNe lasers at 543 or 633 nm were used as excitation sources.
Confocal Z-stacks were collected at 5X zoom at 0.29 mm intervals in a
4 lm total optical depth. Images for direct comparison were collected
using the same parameters and were analysed with the help of IMARIS 7.6
(Bitplane, Zurich, Switzerland) or VOLOCITY 6.0 (PerkinElmer, Waltham,
MA, USA) softwares. Pearson’s correlation coefficient (r) was used for
correlation analysis, with an r value between +0.5 and 1.0 indicating a
high strength of correlation. Omission of the primary antibody was
routinely performed as control for antibody specificity (not shown). The
specificity of the antibody against BACE1 was tested by pre-incubation
of the primary antibody with the BACE peptide (PEP 0077, ThermoFisher,
Waltham, MA, USA), resulting in no staining (not shown).
Amyloid-beta (1-42) ELISA
To measure endogenous amyloid-beta (1-42) levels, a mouse-/rat-
specific and high-sensitive enzyme immunoassay kit was used, according
to the manufacturer’s protocol (code: re45721; IBL Int.).
Statistical analysis
All experiments using SH slices and primary neurons were performed at
least four times independently, each in triplicate. Tissues from four ShcC
KO and four control mice were analysed. The graphs were generated
using PRISM (GraphPad Software, Inc., San Diego, CA, USA), and the data
are presented as the mean  standard error. Student’s t-test or ANOVA
followed by the Tukey–Kramer post hoc was used to analyse the data
depending on the number of variables and groups (Statview-SAS, Cary,
NC, USA). A P value ≤ 0.05 was considered statistically significant.
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